Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Trump Buys SpaceX Shares After Record IPO 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Add as a preferred source on Google
NEW YORK, April 26, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Solid Biosciences Inc. ("Solid Biosciences") (NASDAQ:SLDB) pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra-d/solid-biosciences-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Solid Bioscience’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) the company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
If you suffered a loss in Solid Biosciences you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
